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ABSTRACT
Objective To assess reductions of cerebral glucose
metabolism in Parkinson’s disease (PD) with 18F-
ﬂuorodeoxyglucose (FDG) positron emission tomography
(PET), and their associations with cognitive decline.
Methods FDG-PET was performed on a cohort of 79
patients with newly diagnosed PD (mean disease
duration 8 months) and 20 unrelated controls. PD
participants were scanned while on their usual
dopaminergic medication. Cognitive testing was
performed at baseline, and after 18 months using the
Cognitive Drug Research (CDR) and Cambridge
Neuropsychological Test Automated Battery (CANTAB)
computerised batteries, the Mini-Mental State
Examination (MMSE), and the Montreal Cognitive
Assessment (MoCA). We used statistical parametric
mapping (SPM V.12) software to compare groups and
investigate voxelwise correlations between FDG
metabolism and cognitive score at baseline. Linear
regression was used to evaluate how levels of cortical
FDG metabolism were predictive of subsequent cognitive
decline rated with the MMSE and MoCA.
Results PD participants showed reduced glucose
metabolism in the occipital and inferior parietal lobes
relative to controls. Low performance on memory-based
tasks was associated with reduced FDG metabolism in
posterior parietal and temporal regions, while attentional
performance was associated with more frontal deﬁcits.
Baseline parietal to cerebellum FDG metabolism ratios
predicted MMSE (β=0.38, p=0.001) and MoCA (β=0.3,
p=0.002) at 18 months controlling for baseline score.
Conclusions Reductions in cortical FDG metabolism
were present in newly diagnosed PD, and correlated
with performance on neuropsychological tests. A reduced
baseline parietal metabolism is associated with risk of
cognitive decline and may represent a potential
biomarker for this state and the development of PD
dementia.
INTRODUCTION
Parkinson’s disease (PD) is a progressive neurode-
generative disorder affecting over four million
people above the age of 50, with the prevalence
expected to double to 9.3 million by 2030.1 There
has been a gradual shift in the deﬁnition of PD,
from a primary movement disorder to a multisys-
tem neurodegenerative condition affecting multiple
cognitive domains. Over 40% of early PD cases are
affected by mild cognitive impairment (PD-MCI)2
and up to 80% of patients with PD will eventually
develop dementia (PDD).3
The neural substrates of cognitive impairment in
PD remain poorly understood and there is a need
to establish imaging biomarkers which could aid in
the identiﬁcation of patients at risk of cognitive
decline, for early diagnosis and for therapeutic
trials.
A number of studies have established associations
between low cognitive ratings in prevalent PD and
regional reductions in cortical glucose metabolism,
mostly involving posterior regions.4 5 However,
studies investigating the power of 18F-ﬂuorodeoxyglu-
cose (FDG) positron emission tomography (PET) to
predict later cognitive decline have been fewer, and
chieﬂy performed in small samples with relatively
advanced PD.6–8
The inferior parietal lobe is well established as a
region which shows reduced glucose metabolism
and perfusion in a range of dementias, including
Alzheimer’s disease, dementia with Lewy bodies
(DLB) and PDD. Reduced parietal metabolism is
apparent at the early MCI stage.5 9–11 We hypothe-
sised that reduced FDG metabolism in this region
would be predictive of cognitive decline in early
PD.
In the present study, our aims were to: (1) estab-
lish the pattern of glucose metabolism in early
stage PD relative to healthy controls; (2) investigate
the association between performance on speciﬁc
cognitive tests and levels of regional glucose metab-
olism; (3) to evaluate whether parietal metabolism
predicted cognitive decline over 18 months.
METHODS
Participants
Participants were taking part in the Incidence of
Cognitive Impairment in Cohorts with
Longitudinal Evaluation—Parkinson’s Disease
(ICICLE-PD) study.2 They were newly diagnosed
PD (n=158) from community and outpatient
clinics in the North East of England or unrelated
healthy controls (n=99). PD was diagnosed by a
movement disorders specialist according to the UK
Brain Bank criteria12 and a repeat clinical evalu-
ation was performed at follow-up to increase diag-
nostic accuracy. The ﬁrst 81 PD and 20 controls
who consented to scanning received a FDG-PET
scan. Of the 81 PD participants scanned, 2 were
excluded due to change of diagnosis at follow-up.
Thus, 79 PD participants and 20 healthy controls
who consented to a FDG-PET scan were included
in this study. The PD participants had their PET
scan at baseline, while the controls were scanned
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∼3 years after baseline. Full inclusion and exclusion criteria have
been previously described.2
Standard protocol approvals, registrations and patient
consents
The study was approved by the Newcastle and North Tyneside
Research Ethics Committee and performed according to the
Declaration of Helsinki. All participants provided written
informed consent.
Clinical assessment
Clinical assessments were performed by trained examiners, and
included a standardised neurological examination, with rating of
motor symptoms using the revised Movement Disorders
Society-Uniﬁed Parkinson’s Disease Rating Scale (MDS-UPDRS
III),13 and Hoehn and Yahr14 (H&Y) staging.
Neuropsychological assessment
Global cognitive function was assessed using the Mini-Mental
State Examination (MMSE)15 and the Montreal Cognitive
Assessment (MoCA).16 In accordance with MDS Task Force
recommendations,17 ﬁve cognitive domains were assessed.
Attention was measured using the Cognitive Drug Research
computerised battery.18 Mean response times of simple reaction
time, choice reaction time and digit vigilance were summed to
produce a Power of Attention score. Digit vigilance accuracy
was also evaluated as part of this domain. Power of Attention
(PoA) and Digit Vigilance (DV) data were missing at baseline on
one PD participant. Memory was assessed with Pattern
Recognition Memory (PRM), Spatial Recognition Memory
(SRM), and Paired Associates Learning (PAL) from the compu-
terised Cambridge Neuropsychological Test Automated Battery
(CANTAB).19 Baseline CANTAB data were not acquired on two
PD participants. Executive function was determined using the
modiﬁed One Touch Stockings (OTS) version of the Tower of
London task from CANTAB, phonemic ﬂuency (words begin-
ning with F, A and S in 1 min each) and semantic ﬂuency
(animals in 90 s). Fluency was not performed at baseline on one
PD participant. The pentagon copying item of the MMSE was
graded using a modiﬁed 0–2 rating scale as a measure of visuo-
spatial function. Language domain was assessed using the
naming (0–3) and sentence (0–2) subsets of the MoCA test. All
participants were assessed in an ‘on’ state, taking their usual
dopaminergic medication at baseline and again after 18 months.
Levodopa equivalent daily dose (LEDD) value was calculated
using the Tomlinson et al20 formula. Baseline MoCA was not
performed on the ﬁrst seven PD participants. Assessments were
repeated at 18 months on all the controls, and 90% (71/79) of
the PD participants. Reasons for attrition included loss to
follow-up (n=4), declined follow-up (n=2) and death (n=2).
Participants were diagnosed as PD-MCI if they were impaired
(1.5 SDs) below normative means (derived from controls) on
two or more cognitive tests.2 Consistent with previous method-
ology2 modiﬁed level 2 criteria were used, as our neuropsycho-
logical battery predated the publication of the PD-MCI criteria,
with only one test (ie, pentagon copying) being speciﬁc to the
visuospatial domain.
PET image acquisition
FDG-PET was acquired over 10 min at Newcastle University
using a Siemens Biograph 40 Truepoint PET-CT starting 30 min
after intravenous administration of 250 MBq F-18 FDG.
Siemens software was used for iterative reconstruction
(OSEM2D 6 iterations, 16 subsets) with model-based scatter
correction and attenuation correction based on the CT scan data
obtained immediately before the FDG-PET scan. Participants
were asked to fast for 4 hours preinjection and blood glucose
was tested to ensure it was <180 mg/dL. Participants were
injected in quiet surroundings with minimal distractions and
with their eyes open. The patients with PD were scanned in an
‘on’ state, after taking their usual dopaminergic medication.
PET image processing
Images of FDG metabolism were processed using SPM V.12
software (http://www.ﬁl.ion.ucl.ac.uk/spm/). All images were spa-
tially normalised to an age appropriate FDG-PET template in
Montreal Neurological Institute (MNI) space,21 resampled at
2×2×2 mm, and smoothed with a 8 mm full width half
maximum Gaussian kernel. Voxelwise statistics were performed
with the general linear model in SPM V.12 with image intensity
proportionally scaled to the whole brain mean for each partici-
pant, and using a brain mask of 0.8 mean intensity. Statistics are
shown thresholded either after a voxelwise family wise error
(FWE) correction for multiple comparisons at p<0.05, or with
an uncorrected voxelwise threshold of p<0.001 followed by
p<0.05 FWE clusterwise threshold. Group differences were
performed with age and sex as covariates. Correlation within
the PD group between FDG and cognitive ratings had age, sex
and years of education as covariates.
In our recent FDG study on Alzheimer’s and Lewy body
dementias,9 we found that the ratio of FDG in angular gyrus/
cerebellum was signiﬁcantly reduced in these groups. We there-
fore investigated the power of this ratio to predict cognitive
decline in PD.
Statistical analysis
Statistical analyses were performed using SPSS V.22.0 (IBM,
New York, USA). Means were compared using unpaired t-tests
or analysis of variance. The χ2 test was used to compare categor-
ical variables. Change in cognitive and motor score between
baseline and repeat was assessed with paired t-tests. Linear
regression (continuous dependent variables) was used to investi-
gate the relationship between FDG angular gyrus/cerebellum
ratio and cognitive score (MMSE and MoCA) at 18 months
with baseline score as covariate. Model ﬁt was checked by exam-
ining the residuals.
RESULTS
Participant demographics are shown in table 1. PD and control
groups were well matched for age and sex. There were no sig-
niﬁcant differences between PD with and without MCI at base-
line in disease duration or use of dopaminergic medication,
although the PD-MCI participants had a greater motor severity
and fewer years of education.
Within the PD group, 41 participants were classiﬁed as
PD-MCI at baseline while the remaining 38 PD participants
were classiﬁed as having normal cognitive function (PD-NC).
The PD-MCI group, as expected, performed signiﬁcantly worse
on all neuropsychological assessments than PD-NC and control
participants (see online supplementary table e-1). There were no
signiﬁcant differences in cognition between the control and
PD-NC group in any test, with the exception of SRM, in which
the PD-NC performed marginally worse than controls.
Compared with the control participants, both the cognitively
normal PD and the PD-MCI groups had reduced FDG metabol-
ism in the occipital lobe (ﬁgure 1). The PD-MCI group, in add-
ition, had reduced metabolism in the inferior parietal and
posterior temporal regions. There were, however, no signiﬁcant
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differences between PD-NC and PD-MCI in any region (ie, no
signiﬁcant clusters after p<0.001 uncorrected threshold). In
both PD-NC and PD-MCI, there was a small bilateral region in
the frontal white matter where FDG metabolism was greater
than controls (ﬁgure 2).
In the PD group as a whole, we performed voxelwise correla-
tions between FDG metabolism and cognitive scores at baseline.
Performance on SRM, PAL and OTS correlated with bilateral
parietal–temporal FDG metabolism (poor performance asso-
ciated with reduced metabolism). Furthermore, digit vigilance
accuracy correlated with reduced frontal FDG metabolism
(ﬁgure 3). There were no signiﬁcant correlations for PRM, pen-
tagons or verbal ﬂuency.
The FDG angular gyrus/cerebellum uptake ratio was signiﬁ-
cantly different between groups (F2,96, p<0.001) with the
PD-MCI (ratio=1.05, SD 0.11) being signiﬁcantly lower (Tukey
post hoc p<0.01) than both PD-NC (1.12, SD 0.08) and con-
trols (1.15, SD 0.083) with no signiﬁcant difference between
control and PD-NC. The ratio correlated with MMSE (r=0.28;
p=0.011) and MoCA scores (r=0.27; p=0.024) in the PD
Table 1 Participant demographics
Control (N=20) PD-NC (N=38) PD-MCI (N=41)
Age in years at PET scan [range] 71.9 (9.7) [54–91] 72.3 (6.4) [57–88] 74.2 (4.8) [66–86] F2,96=1.2, p=0.31
Sex M:F 12:8 27:11 30:42 χ2=0.95, p=0.6
Years education 13.9 (3.8) 13.3 (3.6) 10.9 (3.3) F2,96=6.8, p<0.002 b,c
Disease duration at PET (months) [range] – 7.9 (4.9) [2–24] 9.0 (9.3) [1–62] T77=0.6, p=0.5
Baseline assessment to PET scan (months) [range] 43 (2.8) [39–49] 1.9 (1.2) [0.2–4.7] 2.1 (1.3) [0.3–5.9] T77=0.6, p=0.5
Baseline—repeat assessment (months) [range] 20.0 (1.2) [18–24] 18.5 (0.68) [17–20] 18.6 (0.67) [17–20] T77=0.4, p=0.7
LEDD baseline – 144 (115) 191 (140) T77=1.6, p=0.1
LEDD 18 months – 299 (154)** 410 (206)** T69=2.6, p=0.013
UPDRS III baseline – 23.2 (9.0) 28.3 (12.6) T77=2.2, p=0.043
UPDRS III 18 months – 33.5 (12.0)** 37.8 (10.7)** T69=1.6, p=0.1
MMSE baseline 29.5 (0.7) 29.0 (0.9) 27.9 (1.5) F2,96=15, p=0.001 b,c
MMSE 18 months 29.6 (1.0) 28.9 (1.1) 27.1 (1.8)** F2,88=23, p=0.001 b,c
MoCA baseline 27.7 (1.9) 26.3 (2.6) 22.4 (3.6) F2,89=27, p=0.001 b,c
MoCA 18 months 27.6 (2.4) 26.7 (2.6) 23.1 (3.6) F2,88=19, p=0.001 b,c
Comparisons are either three-group ANOVA, or PD-NC versus PD-MCI unpaired t-test, or (for sex) χ2.
Baseline MoCA scores only available on 72 PD participants. Tukey post hoc tests p<0.01, a=PD-NC versus controls, b=PD-MCI versus controls, c=PD-MCI versus PD-NC.
Longitudinal change paired tests: *p<0.05 within group; **p<0.01 within group.
ANOVA, analysis of variance; F, female; LEDD, levodopa equivalent daily dose; M, male; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; PD-MCI,
Parkinson’s disease-mild cognitive impairment; PD-NC, Parkinson’s disease-normal cognitive function; PET, positron emission tomography; UPDRS III, motor subsection of Unified
Parkinson’s Disease Rating Scale.
Figure 1 Regions where FDG metabolism is greater in controls than (A) PD-NC and (B) PD-MCI. FDG uptake is normalised to whole brain. SPM t
image thresholded at p<0.05 FWE corrected for multiple comparisons. FDG, 18F-ﬂuorodeoxyglucose; FWE, family wise error; PD-MCI, Parkinson’s
disease-mild cognitive impairment; PD-NC, Parkinson’s disease-normal cognitive function; SPM, statistical parametric mapping.
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participants at baseline. The FDG angular gyrus/cerebellum
uptake ratio also signiﬁcantly predicted both MMSE and MoCA
at 18 months, controlling for baseline score, age, sex and years
of education. This remained signiﬁcant even after the addition
of disease duration, LEDD, UPDRS III and MCI group at base-
line into the model (table 2). To investigate whether FDG
uptake in other regions predicted MMSE scores longitudinally,
we also performed a voxelwise analysis of MMSE at 18 months
with FDG uptake, controlling for baseline MMSE, age, sex and
education, and found signiﬁcant correlations in the lateral parie-
totemporal–occipital region, but not elsewhere (see online
supplementary ﬁgure S1).
DISCUSSION
This is the largest study to date to examine FDG-PET ﬁndings
in early PD. In this group of newly diagnosed PD, we found
that cortical glucose metabolism was reduced posteriorly, par-
ticularly in the occipital lobe. The PD-MCI participants demon-
strated greater involvement of the parietal and posterior
temporal lobes. Notably, FDG metabolism at baseline in the
angular gyrus relative to cerebellum predicted MMSE and
MoCA scores at 18 months.
Relatively few studies have investigated FDG in early stage
PD. Pappatà et al22 studied 24 newly diagnosed, drug naïve
patients with PD (half with MCI) and found no differences
between cognitively normal PD versus controls, while the
PD-MCI had parieto-occipital (though not primary visual
cortex) and frontal reductions versus controls. The
parieto-occipital reductions were not signiﬁcantly different
between PD-MCI and PD-NC. In PD with 3 years of symptom
duration, Teune et al23 found metabolic reductions in the
occipital pole, inferior parietal and prefrontal cortex, primarily
contralateral to the most affected side. In more advanced PD,
Garcia-Garcia et al10 demonstrated occipital pole and inferior
parietal, and to a lesser extent frontal and temporal FDG reduc-
tions in PD-MCI versus controls. The PD-NC participants did
not show any metabolic differences relative to controls, and
only small differences relative to PD-MCI suggesting that they
fell intermediate between control and PD-MCI. Bohnen et al8
found PD-NC with focal reductions of FDG uptake in the
occipital lobe, while participants with PD and dementia had
more widespread posterior reductions, and Baba et al24 found
that PD with severe olfactory dysfunction were both more likely
to develop dementia, and also had more pronounced
parieto-occipitotemporal FDG reductions.
Although our parieto-occipital changes are broadly in agree-
ment with these studies, we saw fewer frontal FDG reductions in
our PD-MCI group. This may in part be due to differences in
the cognitive tests used to deﬁne MCI. This varies between
studies both in terms of which particular tests are chosen, but
also the number per cognitive domain (the MDS guidelines17
suggest a minimum of two tests per domain, but no maximum).
We had relatively limited assessment of visual and language func-
tion, and our choice of memory tasks were largely dependent on
visual cues, which may have resulted in more posterior metabolic
deﬁcits being identiﬁed. Our participants were scanned and cog-
nitively assessed while taking their usual dopaminergic medica-
tion, and this may have inﬂuenced the scores and FDG uptake.
Eidelberg and colleagues have used principal component ana-
lysis to identify network patterns in PD. They have found two
consistent patterns: (1) a PD-related covariance pattern (PDRP)
of relative increase in the basal ganglia, thalamus and cerebel-
lum, and decrease in premotor and parieto-occipital cortex, and
(2) a PD-related cognitive pattern of reduced FDG in precuneus,
inferior parietal/angular gyrus, pre supplementary motor area
(preSMA), with increases in the cerebellum, the expression of
which increases in patients with poorer cognitive function.4 25
In our study, parietal hypometabolism predicted future cogni-
tive function as measured by MMSE and MoCA at 18 months
controlling for the baseline score. This is in keeping with
smaller studies in more advanced PD6–8 where FDG reductions
in parieto-occipital and temporal regions have been associated
with cognitive decline, or progression to dementia. The inferior
parietal lobes and precuneus region are strongly affected in
Alzheimer’s disease and DLB.9 23 In AD, glucose hypometabo-
lism is a relatively early feature, preceding cortical atrophy, and
predicting cognitive decline at an early stage.11 In PD, this
region shows reduced FDG and blood ﬂow in the absence of
atrophy,5 26 suggesting that in PD also, reduced metabolism is a
relatively early feature, possibly reﬂecting synaptic dysfunction
due to local α-synuclein pathology,27 28 which precedes atrophy
and cognitive decline.
Figure 2 Regions where FDG metabolism is lower in controls than (A) PD-NC and (B) PD-MCI. FDG uptake is normalised to whole brain. SPM t
image thresholded at p<0.05 FWE corrected for multiple comparisons. (cross-hair at −20,36,0). FDG, 18F-ﬂuorodeoxyglucose; FWE, family wise
error; PD-MCI, Parkinson’s disease-mild cognitive impairment; PD-NC, Parkinson’s disease-normal cognitive function; SPM, statistical parametric
mapping.
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We found prominent reduction in FDG of the occipital pole
in all PD participants, and an association was demonstrated
between occipital FDG and performance on PAL (which
requires discrimination of different shapes, and retention of
their location). A number of other studies have also found
occipital FDG reductions in PD,5 8 10 and relatively reduced
occipital FDG is a component of the PDRP.29 Previous research
has found associations of occipital reduction with visuospatial
deﬁcits.10 30 However, the occipital pole hypometabolism is
similar in PD with dementia to cognitively normal PD,10 31
and does not seem related to the severity of motor fea-
tures.32 33 Occipital hypoperfusion/metabolism is also a dis-
tinctive feature of DLB,34 in which it does not vary with
severity of parkinsonism.35 There may be an association with
cholinergic function, since Shimada et al36 established promin-
ent occipital loss of AChE activity (with N-(11C)-methyl-4-
piperidyl acetate) in PD at all stages, and Fong et al37 found
(in a small group of DLB) that acute administration of a cholin-
esterase inhibitor was associated with increased occipitoparietal
perfusion.
Reduced occipital FDG uptake has been associated with rapid
eye movement (REM) sleep behaviour disorder (RBD),38 39 a
clinical feature that may precede or accompany DLB. It may be
that patients with more profound occipital FDG reductions are
at risk of developing clinical features of DLB such as RBD or
visual hallucinations.
Figure 3 Regions where FDG metabolism correlates with cognitive scores. (A) Spatial Recognition Memory, (B) Paired Associates Learning; (C)
One Touch Stockings; (D) Digit Vigilance. In all, higher FDG is associated with better performance. SPM t image voxelwise thresholded at p<0.001
uncorrected for multiple comparisons, signiﬁcant clusters at p<0.05 FWE corrected for multiple comparisons. FDG, 18F-ﬂuorodeoxyglucose; FWE,
family wise error; SPM, statistical parametric mapping.
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Unlike most studies, we acquired FDG-PET imaging with eyes
open. Bohnen et al8 also acquired their data in patients with
eyes open, and they found prominent primary visual deﬁcits in
PD-NC. Using MRI arterial spin labelling in PD-NC with eyes
open, Fernández-Seara et al40 also observed prominent occipital
deﬁcits. Conversely, some of the FDG studies with eyes
closed6 22 did not ﬁnd occipital pole reductions in PD. Occipital
glucose metabolism is generally greater with eyes open.41 It is
possible that patients with PD engage less with the visual envir-
onment due to changes in the retina,42 or cholinergic loss.43 In
this case, the increase in glucose metabolism on eyes opening
would be less marked in PD, and hence any occipital hypometa-
bolism made more obvious compared with control participants.
Further research is required to investigate the origin and impli-
cations of this occipital pole metabolic reduction.
Strengths of our study include the large, well-characterised
cohort at the earliest stages of PD. Weaknesses include the rela-
tively limited testing of visuospatial function. Although we saw
a signiﬁcant correlation between parietal FDG and decline in
MMSE and MoCA, the association was not strong enough to
allow FDG to be used for prediction on an individual basis.
This may partly be due to the limited degree of cognitive
decline in an early PD group over a relatively short period of
follow-up. Also, quantifying change using repeated cognitive
assessment is difﬁcult due to practice effects, and inﬂuence of
factors such as motivation on the scores. With longer follow-up,
the value of baseline FDG scanning and other biomarkers to
predict cognitive decline should become more evident.
In conclusion, we found occipital reductions in a large cohort
of newly diagnosed patients with PD relative to age-matched
controls. Reductions in the temporoparietal region were asso-
ciated with poorer cognitive performance. The FDG parietal/
cerebellar ratio shows some promise for predicting global cogni-
tive decline in early PD.
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impairment; UPDRS III, motor subsection of Unified Parkinson’s Disease Rating Scale.
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